SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as community members rally around the OG meme coin, highlighting its strong community and potential for rebuilding meme culture. Talk centers on bullish sentiment, the importance of community, and the potential for significant growth, with some referencing a possible bottom in the crypto market.

Diginex Ltd. (Hong Kong) is a blockchain financial services and technology company. Its products include diginexESG, diginexLUMEN, diginexAPPRISE, diginexLUMEN Pro, and CSRD framework. The company was founded by Miles Christian Pelham on May 15, 2020 and is headquartered in London, the United Kingdom.

Diginex Ltd.

DGNX is trending due to its recent acquisition of The Remedy Project, sparking discussions about the company's expansion into human-rights remediation. The community is also actively analyzing potential trading strategies based on historical patterns of similar stocks. Options traders are closely monitoring put contracts, anticipating potential downside amidst the volatility.

mF International Ltd. is a holding company, which engages in the development and provision of financial trading solutions through its subsidiary. It offers real-time mission critical forex, bullion and commodities trading platform solutions, financial value-added services, mobile applications, and financial information for brokers and institutional clients via internet or platform as software as a service. The company was founded by Tai Wai Lam and Chi Weng Tam on June 15, 2022, and is headquartered in Hong Kong.

mF International Ltd - Ordinary Shares - Class A

mF International Ltd

mF International ($MFI) is trending due to a recently announced $500M private placement to launch a digital asset treasury strategy, sparking both excitement and skepticism among investors. Some community members speculate about the company becoming a major crypto player, drawing comparisons to MicroStrategy ($MSTR) and highlighting the involvement of figures from the crypto world, while others worry about potential dilution and a pump-and-dump scheme.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zoom Video Communications, Inc.

Zoom ($ZM) is trending as investors anticipate the Q3 earnings report and strategic moves, especially in AI, with analysts pointing to potential upside. The community is actively discussing whether Zoom's partnerships with Oracle and NVIDIA will drive enterprise adoption amid modest revenue growth guidance. Mixed sentiment exists, with some traders betting on a post-earnings surge, while others foresee a continued flatlining or even a decline.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending amidst community discussion around its valuation and future prospects in the quantum computing sector. While some express optimism regarding long-term potential and technological advancements, others highlight concerns about revenue, profitability, and insider selling. Community members are actively debating the stock's fair value and potential catalysts.

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Alvotech

Alvotech ($ALVO) is trending due to recent FDA updates on its biosimilar pipeline, specifically a complete response letter for AVT05 and approval in the European Economic Area for AVT03. The community is actively debating the implications of these regulatory decisions on the company's revenue outlook and potential market share, along with speculation about market manipulation.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as community members promote the memecoin and its association with cannabis culture on the Solana blockchain. The coin is being touted as 'like Bitcoin but way higher' with users sharing links to the project's website and social media.

Meet Pandu — your AI friend who’s always by your side. Talk with him in real time through text or voice, share your thoughts, ask questions, or just enjoy a casual conversation. Whether you’re looking for advice, company, or simply someone to listen, Pandu is here as a true companion you can connect with anytime.  Pandu unites real-time conversation, creative generation, and future-ready AI systems — all powered by next-gen technology.

Pandu Pandas

Pandu Pandas ($PANDU) is trending as community members highlight its strong community, potential for growth, and recent listing on MEXC. The crypto is being discussed for its association with the Solana ecosystem and potential as more than just a meme coin. Chatter includes speculation around upcoming announcements and a potential breakout.

Pony.ai, Inc. develops artificial intelligence-based robot designed for autonomous driving. The firm's software algorithms and infrastructure enables a vehicle to perceive its surroundings, predict what others will do, and maneuver itself accordingly. The company was founded by Jun Peng and Tian Cheng Lou in November 4, 2016 and is headquartered in Guangzhou, China.

Pony AI Inc. - ADR

Pony AI Inc

Pony AI Inc is trending due to the excitement surrounding its expansion and robotaxi initiatives, particularly after securing a permit for driverless robotaxi services in Shanghai. Community discussions revolve around the stock's volatility and potential for growth, with some analysts issuing bullish ratings and price targets. Investors are weighing the company's partnerships, revenue streams, and competition within the autonomous vehicle market.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors discuss its potential to join the trillion-dollar market cap club amid positive analyst outlooks and expected sales growth. Community members are weighing in on AI's impact, the health of the market, and potential opportunities for AMD in comparison to competitors. Semiconductor supply chain developments and potential impacts of trade policies are also being closely monitored.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vir Biotechnology (NASDAQ:VIR) CFO Sells $37,802.44 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) CFO Jason O'byrne sold 6,799 shares of Vir Biotechnology stock in a transaction on Monday, November 17th. The stock was sold at an average price...

Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare...

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven analysts that are presently covering the stock, MarketBeat...

<ul class="summary-bullets"><li>Phase 2 trial showed 66% of patients achieved undetectable hepatitis delta virus RNA with Vir’s tobevibart-elebsiran combo, with no serious safety issues reported.</li><li>Gilead’s rival therapy bulevirtide remains the only approved hepatitis delta treatment in Europe but showed lower long-term response rates in earlier studies.</li><li>VIR trended on Stocktwits as traders highlighted strong efficacy, Gates Foundation backing, and potential for a future head-to-head Phase 3 matchup with Gilead.</li></ul>Vir Biotechnology drew heightened retail attention on Sunday after unveiling new Phase 2 data showing its tobevibart-elebsiran combination achieved high rates of undetectable hepatitis delta virus (HDV) RNA, positioning the therapy as a potential rival to Gilead Sciences’ bulevirtide, which is currently the only approved HDV treatment in Europe.<h2 class="st-heading-2">Vir’s Combination Delivers Strong 48-Week Results</h2>Vir said 66% of participants in its Phase 2 SOLSTICE trial receiving monthly doses of tobevibart and elebsiran achieved undetectable HDV RNA at Week 48, while 90% showed reductions in hepatitis B surface antigen below 10 IU/mL, a marker of suppressed viral replication. Alanine aminotransferase levels normalized in more than half of the participants.The dual regimen was well-tolerated, with no grade 3 or higher treatment-related adverse events or discontinuations. The company said results were consistent even in patients with cirrhosis and high baseline viral load.“Achieving undetectable HDV RNA is a key endpoint in clinical trials, and HDV RNA undetectability is associated with better outcomes for people living with chronic hepatitis delta,” said Tarik Asselah, of the University of Paris-Cité, who presented the data at AASLD’s The Liver Meeting in Washington, D.C.<h2 class="st-heading-2">Eclipse Registration Program Advances</h2>Vir said the combination is now being evaluated in its Eclipse global Phase 3 program, comprising three randomized, controlled trials. Eclipse-1 has completed enrollment ahead of schedule, with topline results from Eclipse-1, -2 and -3 expected in the first quarter of 2027.CEO Marianne De Backer said the new 48-week data “reinforce our confidence that a monthly dose of tobevibart and elebsiran can deliver meaningful patient benefit with convenient dosing.”According to the company, the combination offers the potential to eliminate the virus by tackling the viral lifecycle through multiple mechanisms.<h2 class="st-heading-2">Gilead’s Bulevirtide Demonstrates Durable Off-Treatment Control</h2>In May, Gilead Sciences reported final results from its pivotal Phase 3 MYR301 study showing that 36% of adults treated with bulevirtide maintained virologic suppression for almost two years after stopping therapy. Participants who remained undetectable for one year post-treatment experienced no relapses in the second year of follow-up.Among those with prolonged viral clearance at 96 weeks or later, 90% remained undetectable off-treatment.Gilead said the data underscore bulevirtide’s durability after treatment cessation and the importance of sustained viral suppression during therapy. Bulevirtide 2 mg is the only approved HDV therapy in the EEA, UK, Switzerland, and Australia and is not approved in the U.S.<h2 class="st-heading-2">Stocktwits Traders See ‘Phenomenal’ Data</h2>On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume, placing it among the top ten trending stocks on the platform.<figure class="image"><img style="aspect-ratio:968/142;" src="https://news.stocktwits-cdn.com/vir_ss_jpg_558bd7efe5.webp" alt="vir ss.jpg" width="968" height="142"><figcaption>VIR sentiment and message volume as of November 9 | Source: Stocktwits</figcaption></figure>One user noted that they were encouraged by the company’s strong trial results and high-profile early backers, including the Gates Foundation and Cathie Wood’s ARK Invest, calling the data “phenomenal” and suggesting pre-market trading could reflect the momentum.<stembedurl>https://stocktwits.com/Dunnieboy1/message/635536553</stembedurl>Another investor commented that the trial outcomes appeared “extremely strong,” adding that those who entered the stock before the weekend “may reap rewards” depending on market reaction.<stembedurl>https://stocktwits.com/TDMF123/message/635536478</stembedurl>A third user compared the 66% undetectable HDV RNA rate achieved with Vir’s monthly regimen to what they said was roughly 16% efficacy for Gilead’s bulevirtide, which requires daily injections, describing the results as “good news” ahead of eventual head-to-head Phase 3 testing.<stembedurl>https://stocktwits.com/Dunnieboy1/message/635535478</stembedurl><a href="https://stocktwits.com/symbol/VIR">Vir Biotechnology’s stock</a> has declined 30% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Vir Biotechnology’s stock has declined 30% so far in 2025. (Photo credit: Getty Images)

Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown

Phase 2 trial showed 66% of patients achieved undetectable hepatitis delta virus RNA with Vir’s tobevibart-elebsiran combo, with no serious safety issues reported.

Equity

Vir Biotechnology Announces AASLD The Liver Meeting Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Companys Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonstrated that participants...

Insider Selling: Vir Biotechnology (NASDAQ:VIR) EVP Sells 2,385 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) EVP Verneuil Vanina De sold 2,385 shares of the company's stock in a transaction dated Wednesday, November 5th. The shares were sold at an...

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday...

Vir Biotechnology (NASDAQ:VIR) Releases Quarterly Earnings Results, Misses Expectations By $0.47 EPS

Vir Biotechnology (NASDAQ:VIR - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of...

Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates

Vir Biotechnology (VIR) delivered earnings and revenue surprises of -67.14% and -96.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View

GSK's Q3 earnings and revenue beat expectations, powered by HIV and oncology growth, prompting the company to lift its 2025 outlook.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Current Price	$5.68
Prev Close	$5.56
Open	$5.56
Dividend Yield	0.00%
50-Day Moving Average	$5.62
Beta	1.50
Avg. Volume	1.5M
PE Ratio	-1.57

52-Week High	$14.45
52-Week Low	$4.16
Market Capitalization	$790.23M
EPS (Annual)	-$3.83
Price to Book	0.99
Revenue Per Employee	$181,875.00
Enterprise Value/EBITDA	N/A

VIR
Vir Biotechnology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VIR News

VIRVir Biotechnology Inc